Ferreira, JJ, Stocchi, F, Antonini, A, Rascol, O, Ebersbach, G, Kulisevsky, J, Fonseca, MM, Ramos, D, Rocha, JF, Brigas, HC, Holenz, J, Poewe, W. Early start of opicapone in Parkinson's disease: evidence from a pooled analysis of phase 3 trials for sustained benefit in patients with recent onset of motor fluctuations. Frontiers in Neurology. 2025; 16DOI:10.3389/fneur.2025.1715748. PMID:41473225. IF:2.800(Q2/5D).

Camacho-Meño, L, Labandeira, CM, Bravo, SB, Torres, MV, Bejr-Kasem, H, Molina-Crespo, A, Atienza, M, Lanciego, JL, Cantero, JL, Kulisevsky, J, Labandeira-Garcia, JL, Rodriguez-Perez, AI. Brain-derived extracellular vesicle proteomics reveals neuroprotection induced by the ARB candesartan in Parkinson's disease patients. npj Parkinsons Disease. 2025; 12(1)DOI:10.1038/s41531-025-01230-6. PMID:41366251. IF:8.200(Q1/1D).

Kulisevsky, J, García-Ruíz, P, Outeiro, TF, Gurevich, T, Klivènyi, P, Van Laar, T, Milanov, I, Pirker, W, Popescu, BO, Toft, M, Szász, JA. Pharmacogenetics in advanced Parkinson's disease. JOURNAL OF NEURAL TRANSMISSION. 2025; 132(11)DOI:10.1007/s00702-025-03057-0. PMID:41222708. IF:4.000(Q1/2D).

Garcia-Forn, M, Castany-Pladevall, C, Creus-Muncunill, J, Golbano, A, Escaramís, G, Pérez-Pérez, J, Balantzategi, U, Hernan-Godoy, M, Brito, V, Kulisevsky, J, Martí, E, Pérez-Navarro, E. Sertraline treatment prevents motor dysfunction in a Huntington's disease mouse model and functional decline in patients. Neurotherapeutics. 2025; 22(6)DOI:10.1016/j.neurot.2025.e00716. PMID:40774881. IF:6.900(Q1/1D).